Business & Finance

Amarin posts net loss of $0.09 per share, provides Miraxion development update

Published in Healthcare Finance, Tax and Law Weekly, December 13th, 2006

Amarin Corp. plc (AMRN) reported financial results for the quarter ended September 30, 2006.

For the third quarter of 2006 Amarin reported a net loss of $7.3 million, or $0.09 per share, compared with an adjusted net loss of $5.0 million, or $0.10 per share, in the third quarter of 2005. The increase in net loss primarily reflects Amarin's substantial investment in research and development, particularly in the two fully-enrolled phase III trials with Miraxion in Huntington disease. The net loss for the comparative periods ended September 30, 2005 have been adjusted to reflect the adoption of Financial Reporting Standard 20 (FRS 20) which became effective on January 1,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2006-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry